Media about us

• Prostate Cancer: Epic Sciences AR-V7 Test

  17 August 2017 OncLive

  

  Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center share their views on the Epic Sciences AR-V7 test in development for prostate cancer.

• LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

  16 June 2017 LA BioMed

  

  The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases. Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. 

• OD reports practice’s success with corneal inlay

  15 June 2017 Jeffrey M. Augustine, OD / Healio

  

  The keys to success with the Raindrop Near Vision Inlay are patient selection and evaluation of ocular surface, centration and inflammation, he said. The use of corneal inlays for the surgical correction of presbyopia is an exciting new technology for optometry, ophthalmology and, especially, for the presbyopic patient.

• Pfizer eyes building another plant in Russia

  13 June 2017 ThePharmaLetter

  

  US pharma giant Pfizer (NYSE: PFE) is considering building another manufacturing plant in Russia during the next several years, which is expected to be located in the Tatarstan Republic, one of Russia’s richest and economically developed regions. In addition on May 30, Pfizer officially started building its first Russian plant in the Kaluga Vorsino technopark, which takes place in cooperation with its local partner NovaMedica.

• Russian partnerships: Pfizer and NovaMedica break ground on aseptic plant

  05 June 2017 Dan Stanton / InPharma Technologist

  
  Pfizer and NovaMedica have broken ground on a manufacturing facility in Kaluga set to supply the Russian market with sterile injectable drugs. The ceremony this week comes five months after global pharma firm Pfizer announced it had completed the transfer of the rights and technologies for the production of over.

• The three factors crucial to effectiveness in healthcare

  05 June 2017

  

  SPIEF-2017. Panel discussion "The three factors crucial to effectiveness in healthcare". “The problem and task is to boost the system’s performance within the budget available for now. That does not mean the system needs no more money, that means spending must be efficient,” said Leonid Melamed, Chairman of the Board of Directors, Team Drive.

• Plant to produce Pfizer sterile injectables for Russia gets under way

  01 June 2017 Eric Palmer / Fierce Pharma

  

  Russia's NovaMedica is building a new sterile injectables plant in the Kaluga region where it will produce 30 of Pfizer’s sterile injected generic meds for the local market.

• Construction of a new pharmaceutical plant started in Vorsino Industrial Park

  01 June 2017 GMP News

  

  On May 30, Vorsino Industrial Park in the Kaluga region hosted an official ceremony to mark the start of construction of an advanced biopharmaceutical production facility owned by NovaMedica LLC (a RUSNANO investment project).

• Construction of Pfizer-sponsored pharmaceutical factory starts in Russia

  31 May 2017 Construction.ru

  

  A ground-breaking ceremony of a pharmaceutical factory was held on Tuesday in Vorsino technology park located near the Russian city of Kaluga. American company Pfizer is an investor of the enterprise's building project. The main partner of the project is NovaMedica, a portfolio company of the Russian government-owned company Rusnano engaged in the development of nanotechnology.

• Russia – USA. The bilateral business interest in investment remains high.

  29 May 2017 TASS

  

  In their first talks, Russia’s President Vladimir Putin and the US President Donald Trump noted the importance of restoring full-scale economic partnership, with due account of the fact that in 2016 Russian-American projects started and continued virtually across the entire economy. The numbers include the US investments in Russian export-oriented and import-substituting industries. A number of such projects began in 2016 alone, with Pfizer’s pharmaceutical factory and Novamedica Company in the Kaluga Region among them.